Search Results - "Health technology assessment"

Journal Article

Lack of Cost-Effectiveness of Preoperative Erythropoiesis-Stimulating Agents and/or Iron Therapy in Anaemic, Elective Surgery Patients: A Systematic Review and Updated Analysis

Published in PharmacoEconomics (01.10.2021)

“...OBJECTIVESFor anaemic elective surgery patients, current clinical practice guidelines weakly recommend the routine use of iron, but not erythrocyte-stimulating...”

Journal Article

Lifetime Costs for Treated Follicular Lymphoma Patients in the US

Published in PharmacoEconomics (01.10.2021)

“...BACKGROUND AND OBJECTIVEThe objective of this study was to estimate the lifetime costs of patients receiving treatment for follicular lymphoma (FL) in the...”

Journal Article

Valuing SF-6Dv2 in Australia Using an International Protocol

Published in PharmacoEconomics (01.10.2021)

“...BACKGROUNDThe SF-6Dv2 is an updated version of the SF-6D, with improved consistency and dimension descriptors, and value sets are required. The aim of this...”

Journal Article

Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review

Published in PharmacoEconomics (01.10.2021)

“...INTRODUCTIONThe introduction of immuno-oncology (IO) therapies has changed the treatment landscape of non-small cell lung cancer (NSCLC). Numerous...”

Journal Article

State of the ART? Two New Tools for Risk Communication in Health Technology Assessments

by Grimm, SE Pouwels, X Ramaekers, BLT Wijnen, B Otten, T Grutters, Janneke P.C Joore, MA Published in PharmacoEconomics (2021)

“...Purpose: Outcomes of health technology assessments (HTA) are uncertain, and decision-making is associated with a risk. This risk, consisting of the probability...”

Journal Article

Biased Survival Predictions When Appraising Health Technologies in Heterogeneous Populations

Published in PharmacoEconomics (28.09.2021)

“...INTRODUCTIONTime-to-event data from clinical trials are routinely extrapolated using parametric models to estimate the cost effectiveness of novel therapies,...”

Journal Article

The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe

Published in PharmacoEconomics (04.09.2021)

“...OBJECTIVESThe aim was to outline the challenges of implementing outcomes-based contracts (OBCs) in Europe. METHODSA scoping review was conducted, building on...”

Journal Article

Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment

by Finch, Aureliano Paolo Gamper, Eva Norman, Richard Viney, Rosalie Holzner, Bernhard King, Madeleine Kemmler, Georg Published in PharmacoEconomics (03.07.2021)

“...BACKGROUNDThe EORTC QLU-C10D is a preference-based measure derived from the EORTC QLQ-C30. For use in economic evaluations, country-specific value sets are...”

Journal Article

A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine

by Kirwin, Erin Rafferty, Ellen Harback, Kate Round, Jeff McCabe, Christopher Published in PharmacoEconomics (17.06.2021)

“...OBJECTIVEThe objective of this study was to implement a model-based approach to identify the optimal allocation of a coronavirus disease 2019 (COVID-19)...”

Narrow search